Intellia Therapeutics Gross Profit Over Time
| NTLA Stock | USD 13.80 0.68 5.18% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Intellia Therapeutics Performance and Intellia Therapeutics Correlation. Intellia |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Intellia Therapeutics and related stocks such as Lyra Therapeutics, Hookipa Pharma, and Cingulate Warrants Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYRA | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | (27 K) | (95 K) | 285 K | 296 K | (46.5 M) | (44.1 M) |
| HOOK | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | 7.6 M | 11.9 M | 19.6 M | 18.4 M | 14.2 M | 16.6 M | 12.4 M |
| CINGW | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (178.9 K) | (842.4 K) | (808.4 K) | (622 K) | (582.9 K) | (612.1 K) |
| SABS | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 55.2 M | 59.2 M | 20.6 M | (1.5 M) | (1.4 M) |
| CVKD | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (2 K) | (2.1 K) |
| MNPR | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 122.4 K | 110.2 K | 97.9 K |
| SPRO | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | 335 K | 2 M | 4 M | 4.7 M | 9.3 M | 17.1 M | 47 M | 96.4 M | 101.2 M |
| BOLT | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (40.1 M) | (2.4 M) | 838 K | (53.7 M) | (51 M) |
| CHRS | 1.9 M | 1.9 M | 1.9 M | 2.8 M | 31.1 M | 30 M | 190.1 M | 1.6 M | 1.6 M | 339 M | 438.2 M | 269 M | 141 M | 94.5 M | 141.2 M |
| IKNA | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (35.7 M) | (16.1 M) | 13.6 M | (50.5 M) | (48 M) |
Intellia Therapeutics and related stocks such as Lyra Therapeutics, Hookipa Pharma, and Cingulate Warrants Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Intellia Therapeutics minus its cost of goods sold. It is profit before Intellia Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Intellia Therapeutics | NTLA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 13.8
Check out Intellia Therapeutics Performance and Intellia Therapeutics Correlation. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Intellia Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.